HEALTHCARE-ASSOCIATED INFECTIONS

Flexible, Cost-effective Testing Options That Deliver Timely Results

HEALTHCARE-ACQUIRED INFECTIONS

 

Healthcare-associated Infections (HAIs)—which include bloodstream, gastrointestinal, urinary tract, pulmonary, and surgical site infections—place an enormous burden on both patients and the healthcare system.

According to the CDC, nearly 1 in 31 hospital patients has at least one HAI on any given day.1 Additionally, in 2015, there were about 687,000 HAIs in U.S. acute care hospitals, and approximately 72,000 patients with HAIs died during hospitalization.1 In the U.S. alone, the estimated annual medical cost of HAIs to hospitals and patients ranges from $28.4 to $33.8 billion.2 To put this in perspective, $28 billion comes out to roughly $76 million per day over a full year.

The two critical pathogens noted by the Centers for Medicare and Medicaid Services (CMS)—C. difficile and MRSA—are responsible for nearly 600,000 infections each year.3 It’s estimated that as many as 1 in 3 people are colonized with S. aureus bacteria in their nose, and 1 in every 50 carry MRSA.4 Further, as many as 15% of community-dwelling adults are colonized with C. difficile.5

In response to the challenges presented by antimicrobial resistance, CMS has included specific provisions in its Hospital-Acquired Condition Reduction Program (HACRP) to improve the quality of patient care by reducing the burden of HAIs.6

To this end, the ARIES® C. difficile and MRSA assays can help to improve patient outcomes by providing relevant testing options that integrate into a streamlined diagnostic process. The ARIES® sample-to-answer platform improves operational efficiency by reducing turnaround time, consolidating sample testing, and minimizing opportunities for human error. Our HAI assays are the economically-responsible choice for labs that need to generate actionable results while simultaneously reducing costs.

ARIES® HAI Assays

 

 

Healthcare-associated Infection Resources

 

Can Global Testing for C. difficile Carriers Help Prevent Healthcare-associated CDI?White Paper


ARIES® C. difficile AssaySales Sheet


ARIES® MRSA AssaySales Sheet

  1. HAI Data Portal. HAI Hospital Prevalence Survey. CDC (Internet). Last reviewed October 2018. Available from: https://www.cdc.gov/hai/data/portal/index.html.
  2. Scott, RD II. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention. CDC (Internet). March 2009. Available from: https://www.cdc.gov/hai/pdfs/hai/scott_costpaper.pdf.
  3. Kavanagh K, Calderon L. View Point: Gaps in the Current Guidelines for the Prevention of Methicillin-Resistant Staphylococcus Aureus Surgical Site Infections. Antimicrobial Resistance and Infection Control. BioMed Central (Internet). September 2018. Available from: https://aricjournal.biomedcentral.com/articles/10.1186/s13756-018-0407-0.
  4. MRSA | Healthcare Settings. CDC (Internet). Last reviewed February 2019. Available from: https://www.cdc.gov/mrsa/healthcare/index.html.
  5. Crobach M, Vernon J, Loo V, et al. Understanding Clostridium difficile Colonization. CMR. Mar 2018, 31 (2) e00021-17; DOI: 10.1128/CMR.00021-17. https://doi.org/10.1128/CMR.00021-17.